Cargando…
MRN-100, an Iron-based Compound, Possesses Anti-HIV Activity In Vitro*
We examined the in vitro anti-human immunodeficiency virus (HIV) activity of MRN-100, an iron-based compound derived from bivalent and tervalent ferrates. MRN-100 action against HIV-1 (SF strain) was tested in primary cultures of peripheral blood mononuclear cells (MNC) by analyzing p24 antigen prod...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892344/ https://www.ncbi.nlm.nih.gov/pubmed/18955328 http://dx.doi.org/10.1093/ecam/nen019 |
_version_ | 1782182935828365312 |
---|---|
author | Ghoneum, Mamdooh Shaheen, Magda |
author_facet | Ghoneum, Mamdooh Shaheen, Magda |
author_sort | Ghoneum, Mamdooh |
collection | PubMed |
description | We examined the in vitro anti-human immunodeficiency virus (HIV) activity of MRN-100, an iron-based compound derived from bivalent and tervalent ferrates. MRN-100 action against HIV-1 (SF strain) was tested in primary cultures of peripheral blood mononuclear cells (MNC) by analyzing p24 antigen production and percent survival of MNC infected with HIV. MRN-100 at a concentration of 10% (v/v) inhibited HIV-1 replication in 11 out of 14 samples (79%). The percentage of suppression of p24 antigen was −12.3 to 100% at 10 days post-treatment. MRN-100 also exhibited a significant protective effect in the survival of HIV-1-infected MNC. MNC survival post-treatment was dose dependent, 70.4% ± 8.4, 83.6% ± 10.7 and 90% ± 11.4, at concentrations 2.5, 5 and 10% (v/v), respectively, as compared with 53% ± 4 for HIV-1-infected MNC without treatment. The effect was detected as early as 4 days and continued up to 11 days. Treatment with MRN-100 caused no significant change in proliferative response of MNC alone or cocultured with different mitogens: PHA and Con-A (activators of T cell function) and PWM (activator of CD4(+) T cell-dependent B cells). We concluded that MRN-100 possesses anti-HIV activity in vitro and without an increase in lymphocyte proliferation, MRN-100 may be a useful agent for treating patients with acquired immunodeficiency syndrome. |
format | Text |
id | pubmed-2892344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28923442010-07-29 MRN-100, an Iron-based Compound, Possesses Anti-HIV Activity In Vitro* Ghoneum, Mamdooh Shaheen, Magda Evid Based Complement Alternat Med Original Articles - Basic Science We examined the in vitro anti-human immunodeficiency virus (HIV) activity of MRN-100, an iron-based compound derived from bivalent and tervalent ferrates. MRN-100 action against HIV-1 (SF strain) was tested in primary cultures of peripheral blood mononuclear cells (MNC) by analyzing p24 antigen production and percent survival of MNC infected with HIV. MRN-100 at a concentration of 10% (v/v) inhibited HIV-1 replication in 11 out of 14 samples (79%). The percentage of suppression of p24 antigen was −12.3 to 100% at 10 days post-treatment. MRN-100 also exhibited a significant protective effect in the survival of HIV-1-infected MNC. MNC survival post-treatment was dose dependent, 70.4% ± 8.4, 83.6% ± 10.7 and 90% ± 11.4, at concentrations 2.5, 5 and 10% (v/v), respectively, as compared with 53% ± 4 for HIV-1-infected MNC without treatment. The effect was detected as early as 4 days and continued up to 11 days. Treatment with MRN-100 caused no significant change in proliferative response of MNC alone or cocultured with different mitogens: PHA and Con-A (activators of T cell function) and PWM (activator of CD4(+) T cell-dependent B cells). We concluded that MRN-100 possesses anti-HIV activity in vitro and without an increase in lymphocyte proliferation, MRN-100 may be a useful agent for treating patients with acquired immunodeficiency syndrome. Oxford University Press 2010-12 2008-03-20 /pmc/articles/PMC2892344/ /pubmed/18955328 http://dx.doi.org/10.1093/ecam/nen019 Text en © 2008 The Author(s). http://creativecommons.org/licenses/by-nc/2.0/uk/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles - Basic Science Ghoneum, Mamdooh Shaheen, Magda MRN-100, an Iron-based Compound, Possesses Anti-HIV Activity In Vitro* |
title | MRN-100, an Iron-based Compound, Possesses Anti-HIV Activity In Vitro* |
title_full | MRN-100, an Iron-based Compound, Possesses Anti-HIV Activity In Vitro* |
title_fullStr | MRN-100, an Iron-based Compound, Possesses Anti-HIV Activity In Vitro* |
title_full_unstemmed | MRN-100, an Iron-based Compound, Possesses Anti-HIV Activity In Vitro* |
title_short | MRN-100, an Iron-based Compound, Possesses Anti-HIV Activity In Vitro* |
title_sort | mrn-100, an iron-based compound, possesses anti-hiv activity in vitro* |
topic | Original Articles - Basic Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892344/ https://www.ncbi.nlm.nih.gov/pubmed/18955328 http://dx.doi.org/10.1093/ecam/nen019 |
work_keys_str_mv | AT ghoneummamdooh mrn100anironbasedcompoundpossessesantihivactivityinvitro AT shaheenmagda mrn100anironbasedcompoundpossessesantihivactivityinvitro |